TY - JOUR
T1 - Three-year outcome data of second-line antiretroviral therapy in Ugandan adults
T2 - Good virological response but high rate of toxicity
AU - Castelnuovo, Barbara
AU - John, Laurence
AU - Lutwama, Fred
AU - Ronald, Allan
AU - Spacek, Lisa A.
AU - Bates, Michael
AU - Kamya, Moses R.
AU - Colebunders, Robert
PY - 2009/1
Y1 - 2009/1
N2 - Objective. To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen. Design. Prospective 36 months cohort study of patients switched to zidovudine/stavudine plus didanosine plus lopinavir/ritonavir capsules as second-line regimen. Methodology. Structured interview, medical examination, and laboratory assessment performed every 6 months. Results. We enrolled 40 patients; 1 died and 3 were lost to follow-up. Median CD4+ count at baseline was 108 cell/μL, median log viral load was 4.8 copies/mL. Sixteen (40%) patients had baseline genotypic resistant test, 14 (87%) had lamivudine resistance mutations, and all had NNRTIs resistance mutations. At month 36, 82% of the patients achieved viral suppression (
AB - Objective. To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen. Design. Prospective 36 months cohort study of patients switched to zidovudine/stavudine plus didanosine plus lopinavir/ritonavir capsules as second-line regimen. Methodology. Structured interview, medical examination, and laboratory assessment performed every 6 months. Results. We enrolled 40 patients; 1 died and 3 were lost to follow-up. Median CD4+ count at baseline was 108 cell/μL, median log viral load was 4.8 copies/mL. Sixteen (40%) patients had baseline genotypic resistant test, 14 (87%) had lamivudine resistance mutations, and all had NNRTIs resistance mutations. At month 36, 82% of the patients achieved viral suppression (
KW - resource-limited settings
KW - second-line antiretroviral therapy
KW - virological response
UR - http://www.scopus.com/inward/record.url?scp=67649364115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649364115&partnerID=8YFLogxK
U2 - 10.1177/1545109708328538
DO - 10.1177/1545109708328538
M3 - Article
C2 - 19095630
AN - SCOPUS:67649364115
SN - 1545-1097
VL - 8
SP - 52
EP - 59
JO - Journal of the International Association of Physicians in AIDS Care
JF - Journal of the International Association of Physicians in AIDS Care
IS - 1
ER -